Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lantern Pharma Inc.'s SEC filings document a clinical-stage oncology company built around AI-enabled drug development, its RADR platform and related research technologies. The filings include Form 8-K reports for financial results, Regulation FD presentations, and demonstrations of withZeta.ai, including platform capabilities, commercial architecture, rare-cancer research applications and revenue strategy disclosures.
Proxy and annual-meeting filings cover board elections, equity incentive plan matters, option repricing, independent auditor ratification and stockholder voting results. The filing record also includes exhibit-based press releases and presentations, Inline XBRL cover data, and forward-looking-statement risk language tied to Lantern Pharma's clinical programs, AI platforms, capital needs and development-stage biotechnology operations.
Lantern Pharma (LTRN) director Lee T. Schalop was granted a stock option award for 5,000 shares under the companys Amended and Restated 2018 Equity Incentive Plan. The option has an exercise price of $4.46 and was granted with a transaction date of 08/19/2025. The award becomes exercisable in equal monthly increments over a 36-month vesting period commencing 09/19/2025 and expires 08/18/2035. The filing reports 5,000 underlying shares held directly following the grant. The Form 4 was submitted by the reporting person, who is identified as a director of the issuer.
Lantern Pharma Inc. reported in a Current Report on Form 8-K dated August 13, 2025 that it will issue a press release announcing its financial results for the second quarter ended June 30, 2025. The Company furnished the press release as Exhibit 99.1 and included a cover page interactive data file as Exhibit 104.
The filing notes the disclosure is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other filings. The document identifies Lantern Pharma as an emerging growth company, indicates it elected not to use the extended transition period for new accounting standards, lists its Nasdaq ticker LTRN, principal executive office in Dallas, Texas, and is signed by CFO David R. Margrave.
Lantern Pharma Inc. (LTRN) reported continuing operating losses as it advances three clinical-stage small-molecule candidates and an ADC program while relying on its RADR® A.I. platform. For the six months ended June 30, 2025, the company recorded a net loss of $8,867,798 versus $10,400,316 a year earlier, and net loss per share of $0.82 versus $0.97. Cash and cash equivalents were $6,061,408 and marketable securities were $9,840,366, giving approximately $15.9 million of combined liquidity and working capital of about $12.3 million.
The company noted a substantial doubt about its ability to continue as a going concern absent additional financing but expects existing resources to fund operations into June 2026. In July 2025 Lantern entered an ATM Sales Agreement to offer up to $15.53 million of common stock and sold 15,185 shares for approximately $80,000 through August 12, 2025. Research and development expense decreased to $6.33 million for the six months ended June 30, 2025 from $8.14 million a year earlier, while general and administrative expense was roughly stable at about $3.09 million. The company continues active clinical programs for LP-300 (Phase 2), LP-184 (Phase 1) and LP-284 (Phase 1) and operates the RADR platform and a Starlight subsidiary for CNS development.
Lantern Pharma Inc. will hold its 2025 virtual Annual Meeting on September 19, 2025 at 11:00 a.m. Eastern. Only holders of record as of July 28, 2025 may vote; 10,784,725 shares of common stock were outstanding on the record date. Stockholders will vote to elect six directors, approve a one-time repricing of certain stock options under the 2018 Equity Incentive Plan, ratify EisnerAmper LLP as auditor, and approve an adjournment if needed.
The Board approved the repricing on July 24, 2025: Eligible options have exercise prices > $10 and total 314,633 options (about 25% of 1,235,331 outstanding options) are eligible. Subject to stockholder approval, those options would be amended to an exercise price of $5.04 (125% of the 10-day VWAP ending July 24) and will only be exercisable at that price if the holder remains a service provider through a vesting satisfaction date 12 months after stockholder approval. The Company will recognize any incremental compensation cost under ASC Topic 718. The Board recommends a vote FOR all proposals.